Skip to main content
. 2022 Oct 21;28(39):5750–5763. doi: 10.3748/wjg.v28.i39.5750

Table 2.

Univariate and multivariate predictors of overall survival > 12 mo among patients with malignancy using immune checkpoint inhibitor (n = 128)

Clinical variables
Univariate predictors
Multivariate predictors
OR
95%CI
P value
OR
95%CI
P value
Demographics
Age (yr) 1.00 0.97-1.03 0.970
Male 0.92 0.45-1.87 0.822
Female 1.08 0.53-2.20 0.822
Race
White 1.37 0.58-3.25 0.473
Black 2.39 0.24-23.6 0.456
Asian 0.97 0.25-3.79 0.965
Other 0.45 0.14-1.45 0.181
Type of malignancy
Melanoma 0.87 0.43-1.74 0.688
RCC 1.65 0.53-5.12 0.390
NSCLC 2.52 0.65-9.80 0.181
Sarcoma 0.15 0.03-0.72 0.018 0.17 0.03-0.95 0.043
Head and neck SCC 1.04 0.22-4.84 0.961
Other 1.50 0.52-4.35 0.453
Presence of IMC 2.16 1.06-4.41 0.034 2.81 1.17-6.77 0.021
Presence of high grade IMC 0.47 0.16-1.38 0.167
Stage IV malignancy 0.48 0.14-1.61 0.233
Type of Immune Checkpoint Inhibitor
Ipilimumab plus nivolumab 1.32 0.30-5.77 0.714
Ipilimumab 0.74 0.29-1.85 0.517
Nivolumab 1.63 0.46-5.70 0.448
Pembrolizumab 2.93 1.27-6.73 0.011 1.06 0.38-2.98 0.911
Atezolizumab 1.32 0.30-5.77 0.714
Number of ICI infusionsa 1.19 1.08-1.32 0.001 1.23 1.09-1.40 0.001
Dose of ICI (mg/kg) 1.33 0.86-2.05 0.198
Prior ICI use 0.51 0.19-1.37 0.183
Medical history
Non-liver, non-upper GI diseaseb 0.87 0.38-2.02 0.747
Personal history of autoimmune diseaseb 1.47 0.63-3.40 0.373
Family history of autoimmune diseaseb 1.03 0.32-4.41 0.804
Prior irAE 2.84 0.31 - 25.9 0.356
Prior immune-enhancing therapyb 0.62 0.18-2.15 0.454
Vitamin D use 0.60 0.28-1.29 0.190
Smoking (current or prior) 0.74 0.37-1.50 0.410
NSAID use 1.04 0.41-2.69 0.928
Any vaccine 0.36 0.14-0.89 0.026 1.03 0.16-6.70 0.972
Flu vaccine 0.22 0.08-0.67 0.007 0.30 0.04-2.31 0.248
Pneumonia vaccine 0.41 0.11-1.48 0.175
Other vaccine 0.77 0.05-12.66 0.858
Weight at start of ICI (kg) 0.99 0.97-1.01 0.207
Medications
Steroid at start of ICI 0.74 0.29-1.93 0.541
Steroid duration (d) 1.00 0.997-1.01 0.368
Infliximab use 0.76 0.21-2.77 0.226
Vedolizumab use 1.00 0.99-1.01 1.000
a

Number of infusions of immune checkpoint inhibitor prior to immune checkpoint inhibitor-mediated colitis diagnosis (cases) or total (controls).

ICI: Immune checkpoint inhibitor; IMC: Immune checkpoint inhibitor-mediated colitis; OR: Odds ratios; CI: Confidence interval; SD: Standard deviation; RCC: Renal cell carcinoma; NSCLC: Non-small cell lung cancer; SCC: Squamous cell carcinoma; irAE: Immune related adverse event.